Compare American Airlines Group Inc (AAL) vs Adaptive Biotechnologies Corp (ADPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Adaptive Biotechnologies Corp — how do they compare? American Airlines Group Inc trades at $15.38 (market cap $10.55B), while Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B). The key difference: American Airlines Group Inc is far larger — about 2.6× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, American Airlines Group Inc nearer its low. Which is the better fit depends on your goals.
| AAL | ADPT | |
|---|---|---|
Market Cap | $10.55B | $4.04B |
Sector | Industrials | Health |
52-Week High | $18.15 | $25.45 |
52-Week Low | $10.18 | $12.30 |
Enterprise Value | $38.51B | $4.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.00, down 5.9% in the last 24 hours, with technical indicators signaling a bearish trend near support at $14. The company reported mixed earnings, beating estimates in Q1 and Q2 2026 but missing in Q4 2025, with revenue growth to $54.63 billion in 2025. However, net income margin remains negative at -0.56%, and high debt levels persist despite a declining trend.
AAL's outlook is cautious; while analyst consensus is a buy with a $19.63 price target, risks include volatile fuel costs, leverage, and thin profitability. The stock offers potential upside if premium revenue growth sustains, but investors face headwinds from operational margins and economic sensitivity.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →
